Valeant Pharmaceuticals International, Inc.’s (TSX: VRX) stock has recently been a target of a report published by Citron Research, accusing the pharma giant of inflating sales using phantom pharmacies. Andrew Left, Citron’s creator, issues reports laced with profanity, as well as vivid anatomical descriptions and taunts directed at corporate executives, in an effort to short sell the shares. Of the 111 Citron short-sale reports published from 2001 to 2014, there was an average share-price decline of 42% in the year after it was released. Such accusations could weigh on the entire Canadian pharma sector, including the stocks on our list today.
Concordia Healthcare Corp. (TSX: CXR) – $43.71
Pharmaceuticals
Concordia Healthcare Corp. is a Canada-based diverse healthcare company focused on legacy pharmaceutical products and orphan drugs. The Company operates through three segments, which includes Legacy Pharmaceutical Division, Concordia Pharmaceuticals Inc., which consists of 23 products, including Nilandron, for the treatment of metastatic prostate cancer; Dibenzyline, for the treatment of pheochromocytoma; Lanoxin, for the treatment of mild-to-moderate heart failure and atrial fibrillation; Plaquenil, for the treatment of lupus and rheumatoid arthritis; Donnatal, for the treatment of irritable bowel syndrome, and Zonegran (zonisamide), for treatment of partial seizures in adults with epilepsy.
- Market Cap: $1,507,941,190
- Revenues (LTM): $233,670,018
- Total Equity (LFQ): $699,234,938
- WTD Price Change: -14.1%
ProMetic Life Sciences Inc. (TSX: PLI) – $1.78
Pharmaceuticals
ProMetic Life Sciences Inc. (ProMetic) is a Canada-based biopharmaceutical company that offers solutions in bioseparations, plasma-derived therapeutics and small-molecule drug development. ProMetic offers its technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens. The Company operates through two segments: Therapeutics and Protein Technology.
- Market Cap: $1,057,444,768
- Revenues (LTM): $17,668,000
- Total Equity (LFQ): $133,311,000
- WTD Price Change: -5.7%
Knight Therapeutics Inc. (TSX: GUD) – $7.47
Pharmaceuticals
Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. Its principal business activity is developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products in Canada and internationally. The Company has a portfolio of products in various stages of development for various geographies that include Impavido, ATryn, Photofrin, FOCUSfactor, NXN-1882 (nNOS/5HT), NXN-4622 (nNOS) and nNOS/iNOS2 Inhibitor.
- Market Cap: $762,617,281
- Revenues (LTM): $696,540
- Total Equity (LFQ): $526,339,090
- WTD Price Change: 1.0%
Looking for more hidden gems? Get your free Mining 20 Monthly report.
The Ubika Mining 20 index (UM20) climbed 7.1% during the past month, compared with a 12.1% gain by the TSX Mining Index, outperforming the TSX Venture Index during this time. Sierra Metals Inc. (TSX: SMT) was the top-performing component this month, powering 33% higher after reporting production increases from its two mines in Mexico.
Get your copy of the Ubika Mining 20 report here >>
Merus Labs International Inc. (TSX: MSL) – $1.76
Pharmaceuticals
Merus Labs International Inc. (Merus) is a specialty pharmaceutical company engaged in the acquisition and licensing of branded prescription pharmaceutical products in Canada and internationally. It carries out business principally in Canada and Europe. The Company has products in the area of urology/women’s health and anti-infectives. Its products include Factive, Emselex/Enable and Vancocin.
- Market Cap: $175,289,115
- Revenues (LTM): $38,832,970
- Total Equity (LFQ): $175,020,860
- WTD Price Change: -2.8%
Cardiome Pharma Corp. (TSX: COM) – $10.25
Pharmaceuticals
Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company that is focused on the development and commercialization of cardiovascular therapies that improve the life and health of patients suffering from heart disease. The Company has two marketed, in-hospital, cardiology products, BRINAVESSTM and AGGRASTAT, which are commercially available in markets outside of the United States.
- Market Cap: $175,043,312
- Revenues (LTM): $30,986,264
- Total Equity (LFQ): $12,764,553
- WTD Price Change: -10.5%
